Tamoxifen's Role in Breast Cancer Prevention
Author Information
Author(s): Laura J Esserman, Elissa M Ozanne, Mitch Dowsett, Joyce M Slingerland
Primary Institution: University of California San Francisco Medical Center
Hypothesis
Can tamoxifen reduce the risk of both ER+ and ER- breast cancers and promote the transformation of ER+ cancers to ER- cancers?
Conclusion
Tamoxifen may promote the development of ER- cancers from ER+ precursors.
Supporting Evidence
- Tamoxifen reduced the incidence of ER+ tumors by 69% in the BCPT trial.
- 44% of contralateral cancers in women over 50 who received tamoxifen were ER-.
- The model predicts a transformation rate of approximately 20% of ER+ tumors to ER-.
Takeaway
Tamoxifen might help prevent some types of breast cancer, but it could also cause some cancers to change from one type to another.
Methodology
Data from the Breast Cancer Prevention Trial (BCPT) and Multiple Outcomes of Raloxifene (MORE) were analyzed to assess tamoxifen's effects on ER+ and ER- tumors.
Potential Biases
Potential biases may arise from the selection of trial participants and the retrospective nature of data analysis.
Limitations
The study relies on data from previous trials, which may not fully capture the effects of tamoxifen in all populations.
Participant Demographics
The study included high-risk postmenopausal women aged 35 years or older.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website